Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. - Wikidata - awgldk - TriplyDB

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

http://www.wikidata.org/entity/Q33151135

about

Light chain (AL) amyloidosis: update on diagnosis and management The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment Update on treatment of light chain amyloidosis Amyloid diseases of the heart: current and future therapies Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.Amyloidosis and POEMS syndrome.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Cancer-testis antigen expression and immunogenicity in AL amyloidosis.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs Perspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Treatment of plasma cell dyscrasias with lenalidomide.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.The risk of renal disease is increased in lambda myeloma with bone marrow amyloid deposits Treatment of immunoglobulin light chain amyloidosis.Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.Light-chain amyloidosis: SCT, novel agents and beyond.Light chain amyloidosis 2012: a new era.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.Immunoglobulin light chain amyloidosis.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.Preclinical development of siRNA therapeutics for AL amyloidosis.Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.How to manage primary amyloidosis.Cardiac amyloidosis--sustained clinical and free light chain response to low dose thalidomide and corticosteroids.Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.

P2860

Q21198863-4C713FA9-8307-48FA-89EC-59DA6473CAA0 Q26740439-67F00236-A734-4D92-9D47-A8999C44F191 Q26827340-A9AE728F-E7A0-4829-9355-95BD9DC8BAFC Q26829735-01CC0B29-721C-42B9-9CE6-B1269246062C Q27023836-F52C6520-DF33-43C0-A80A-EAA685394C1C Q33288696-3FC7B391-1098-4723-9A61-BD0AF6A42D64 Q33292965-52ACCA0C-8320-409C-BEEA-09BBECEA226A Q33417805-BF69BB33-C01E-4FB8-A511-93230DF6A55F Q33867198-57121863-6CF8-4208-8F1B-BFE6B8F75B45 Q34253548-F233EB92-89B3-45E4-9529-C4D3FBE11875 Q34448455-98F3704E-CC25-4F85-A902-1CFCB14098BB Q34450910-290FA09D-4420-4F0A-86B3-D29D57DD7CBB Q36015183-B710CDD9-5775-4EE4-A5BD-5A98505FC7AC Q36163205-7C67DE7A-FB38-456A-ADFE-351EB30545C0 Q36171864-6347726F-4EA6-41D8-ADC0-0BE5D658FE26 Q36289604-7DDDC403-1DF1-4F57-90C3-27680BACFDF5 Q36910372-4A90C461-60AB-458B-BD45-53FBE5F50424 Q36950813-F2C68958-70D3-4354-8642-ECF0C1ED06FF Q37045885-72F3BDD7-6806-4011-9085-6F162E359984 Q37045900-2856A3FA-3FAE-41C2-A5EE-528206CF34D9 Q37176044-6D4FBE78-6C6F-4A85-9BAE-2539FD29DC4F Q37212712-7CBDE199-70B6-4E45-B8A3-7065E8488A0E Q37693762-918E0405-BFF2-4A38-A414-758E61F31252 Q37738576-ECCB7877-9D55-452D-9F1A-771021AB23B9 Q37832199-81C03B20-A036-4D27-AB4B-529FE760D14F Q38056010-C2ABABD1-A83C-4DA5-83E3-276655656ED6 Q38072108-0E3105D7-9394-4A95-8ED1-4B1800ADC1B1 Q38100588-A9BA8426-BBEB-4D4B-8895-4276F159138C Q38172295-C8DC7AE1-59C4-4525-ACCB-984A6BE15082 Q38928383-04D361EC-BF3B-4630-AC1C-8DACDB63FC98 Q40362742-98022A03-2337-40E4-9542-BF60BF081DE1 Q41433373-557829B6-CB17-4884-B1D5-1BEBAE4B5799 Q42867066-62093193-D9B7-40DC-881C-30014943CCB1 Q43050098-1A4FE16B-2816-4E23-941B-4D8307434C49 Q46400142-88F6B7DF-5487-4BDE-AD16-A1F5083B36DA Q46939620-41C3A7AB-0BF9-4A34-B829-62BAD29B5A9D Q48614453-86EB1804-F8B2-41FA-8A06-49926F43EE81 Q52716575-211FDF4A-034A-43E0-9EE4-108E0F8AA4E7 Q53504425-0F7C79E3-0D85-4E7E-A946-FD0EB88450E5 Q55023498-0AB35D41-595D-4545-B49F-2B62B4CF7B42

P2860

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

http://www.wikidata.org/entity/Q33151135

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@ast

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@en

type

label

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@ast

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@en

prefLabel

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@ast

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@en

P1433

Q33151135-CCC3CB90-CC36-4569-B190-47D1D7EEFF56

P1476

Q33151135-CF32A6F3-527E-4547-8FFF-44CFF904E06C

P2093

Q33151135-0293D27F-6089-41DB-9665-8BCFC891B4A7

Q33151135-12C26F8D-F8A4-4F77-9950-3DC6BC6EE655

Q33151135-2828F08A-5C7D-4FA2-BC74-5FB6A4817C9C

Q33151135-33F49B8F-CBC7-4F56-8561-241562DAC8AA

Q33151135-7950A095-319C-4C8D-9433-33156B10ACE1

P2860

Q33151135-2AA89273-82D3-4155-A2B7-F7B3DB7BA46F

Q33151135-49E4440B-56CB-49F0-AD0F-5EAC9E2F2AB5

Q33151135-54DA98CF-8CFB-4A6B-AC56-6C138459116C

Q33151135-58A678AF-746F-4B07-BA41-775409CC74B3

Q33151135-7E855B5F-CEBA-4DD6-BFF6-6F8BA7813AFE

Q33151135-DD36DE8F-FB02-4112-A3FA-0FA775B9DBE2

Q33151135-E9A5AB41-44D2-4CF4-9F4A-839093C238B8

Q33151135-F5DA2369-2C99-44BA-8F67-30CC7D7D8E15

P304

Q33151135-880966C9-BFB7-44B3-A8F6-4DDA09D2DE5C

P31

Q33151135-18BC4628-5C42-48A8-B811-6A91219D5833

P356

Q33151135-21D5F607-8A03-45EB-A8DF-9234ECC7FFE3

P433

Q33151135-B1F3AAEB-0342-42A7-99D1-0616837F2E4F

P478

Q33151135-B4B76922-7D39-4735-9EB3-F5937091A4E4

P50

Q33151135-34051155-F195-4762-ACBA-B561FA32FB9B

Q33151135-4108712A-5B85-41C7-8B78-24C5AD953B24

Q33151135-570AEA86-28F2-4243-B3CD-BA1F1E3E2E6D

Q33151135-8A85C800-680A-4478-A827-4ABCF8E95061

Q33151135-D254EFF8-B6B8-415D-9264-9271B6D73F4C

P577

Q33151135-1784CC7C-AE58-4CCE-A501-DE57CABEF053

P698

Q33151135-D34F233B-97CB-4E94-9462-97C36447B160

P921

Q33151135-DE366330-72DE-400A-9249-360928D41894

P356

13506120309041743

P1433

P1476

Poor tolerance to high doses o ...... primary systemic amyloidosis.

@en

P2093

John A Lust

http://www.w3.org/2001/XMLSchema#string

Philip R Greipp

http://www.w3.org/2001/XMLSchema#string

Rafael Fonseca

http://www.w3.org/2001/XMLSchema#string

Susan M Geyer

http://www.w3.org/2001/XMLSchema#string

Thomas E Witzig

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Thalidomide for previously untreated indolent or smoldering multiple myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia.

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.

Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis.

P304

257-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/13506120309041743

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

S. Vincent Rajkumar

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14986485

http://www.w3.org/2001/XMLSchema#string

P921